Actinium Pharmaceuticals ATNM

NYSE ATNM

$1.23 +0.00 (+0.00%)

As of: Sep 9, 2026 · 3:58 PM EDT

Key Stats

Market Cap38.93 Mn

P/E3.44

P/S1.11

Div. Yield0.00

Add ratio to table…

About

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. The company employs a biology-driven approach to create differentiated, first-in-class radiopharmaceutical therapeutics for patients with solid tumors and hematologic malignancies. By combining deep understanding of tumor biology and translational medicine with expertise in radiochemistry,…

Actinium generates revenue through the development and potential commercialization of its radiopharmaceutical product candidates. The company's pipeline includes ATNM-400 and Actimab-A for solid tumors, and Iomab-B and Iomab-ACT as targeted conditioning agents for bone marrow transplant and cell and gene therapies. Revenue is expected to arise from future product sales, strategic partnerships, licensing agreements, and potential milestones as programs advance through clinical development toward regulatory approval and market launch.

The company operates through the following segments: Solid Tumor Programs, Hematology Programs, and Targeted Conditioning Franchise.

Solid Tumor Programs: This segment includes ATNM-400, a first-in-class Ac-225 antibody radioconjugate targeting a novel, non-PSMA antigen with expression across multiple solid tumor types. ATNM-400 has demonstrated preclinical activity in metastatic castration-resistant prostate cancer, non-small cell lung cancer, and breast cancer. The segment also includes Actimab-A, which is being developed to deplete CD33+ myeloid-derived suppressor cells in the tumor microenvironment to enhance checkpoint inhibitor efficacy in solid tumors.
Hematology Programs: This segment features Actimab-A as a CD33-targeted therapy being developed as a mutation-agnostic backbone therapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. Actimab-A is being evaluated in combination with CLAG-M chemotherapy for relapsed/refractory AML and in other settings such as frontline AML triplet combinations and high-risk MDS monotherapy. The program is supported by a Cooperative Research and Development Agreement with the National Cancer Institute.
Targeted Conditioning Franchise: This segment includes Iomab-B and Iomab-ACT, both CD45-targeted conditioning agents. Iomab-B is designed to enable bone marrow transplant in relapsed/refractory AML patients ineligible for conventional conditioning, while Iomab-ACT is being developed as a universal conditioning agent to improve access and outcomes for cell and gene therapies including CAR-T and allogeneic hematopoietic stem cell transplant. Iomab-ACT is currently under evaluation in three active clinical trials for commercial CAR-T, experimental CAR-T, and sickle cell disease bone marrow transplant.

Actinium positions itself as a differentiated player in the radiopharmaceutical therapeutics field by focusing on novel, first-in-class targets not widely pursued by competitors. While many companies concentrate on PSMA, SSTR2, and FAP targets, Actinium's pipeline addresses distinct biological mechanisms such as myeloid-derived suppressor cells and CD33/CD45 pathways. The company's competitive strengths include its biology-driven approach, vertically integrated capabilities spanning isotope production to drug manufacturing, late-stage hematology programs with FDA alignment, and a strong intellectual property portfolio of approximately 250 issued patents and pending applications.

Actinium serves patients with oncology and hematologic conditions, including those with solid tumors such as prostate cancer, non-small cell lung cancer, and breast cancer, as well as patients with hematologic malignancies like acute myeloid leukemia and myelodysplastic syndrome. The company's product candidates are intended for administration in clinical settings such as hospitals, cancer centers, and transplant facilities, with development supported by relationships with leading comprehensive cancer centers and clinical trial sites across the United States and Europe.

Investment Thesis

▲ Bull case

Actinium Pharmaceuticals (ATNM) is advancing a unique mutation-agnostic therapeutic platform centered on its lead candidate ATNM-400, a non-PSMA-targeted Actinium-225 antibody radioconjugate that demonstrates robust preclinical efficacy across multiple solid tumors including prostate cancer, non-small cell lung cancer (NSCLC), and breast cancer. Unlike PSMA-targeted therapies such as Pluvicto, which are limited by antigen heterogeneity and resistance mechanisms, ATNM-400 targets a novel antigen expressed in approximately 98% of NSCLC tumors and upregulated in resistant models, enabling activity in PSMA-negative and ARPI-resistant settings where current standards of care fail. This broad target expression, combined with evidence of synergistic effects when combined with EGFR or KRAS inhibitors—such as osimertinib yielding 107% tumor growth inhibition—positions ATNM-400 not as a niche agent but as a potential backbone therapy capable of enhancing existing standard-of-care regimens in large, commercially significant markets. The company’s focus on overcoming resistance mechanisms rather than competing in crowded mutation-specific lanes represents a structural shift in how targeted radiotherapies could be developed, with ATNM-400 poised to address unmet needs in patient populations exceeding 100,000 annually in mCRPC alone and tapping into NSCLC segments with peak sales estimates over $15 billion for EGFR inhibitors and $5 billion for KRAS inhibitors.
Actinium’s intellectual property strategy is reinforcing long-term defensibility and global scalability of its core programs, as evidenced by recent Notices of Allowance from the Canadian Intellectual Property Office (CIPO) for key patents covering Actimab-A in combination with CLAG-M for AML and Iomab-ACT for gene-edited cell-based therapies. These allowances, which build on existing protections in the U.S., Japan, and pending applications in Europe and China, extend patent coverage into 2038–2039, securing exclusivity for two of the company’s most advanced clinical-stage franchises. The Actimab-A patent protects a differentiated immunotherapy-chemotherapy backbone showing improved survival in relapsed/refractory AML, while the Iomab-ACT patent covers a targeted CD45 conditioning agent critical for enabling next-generation adoptive cell therapies, including gene-edited approaches like CAR-T. This expanding global IP estate—now encompassing approximately 250 issued and pending patents—creates formidable barriers to entry, supports premium partnership potential, and increases the likelihood of favorable outcomes in ongoing collaborations with institutions like the National Cancer Institute (NCI), thereby reducing execution risk and enhancing commercial leverage as these programs advance toward pivotal trials.
ATNM is leveraging its proprietary radiochemistry expertise to overcome a critical bottleneck in radiopharmaceutical development: chelator-to-antibody ratio (CAR) optimization. Recent SNMMI 2026 data demonstrated that precise CAR calibration directly improves tumor targeting, internalization, pharmacokinetics, and therapeutic index of 225Ac-labeled antibodies—turning a common formulation challenge into a proprietary advantage. Too low a CAR results in insufficient radiation delivery; too high causes antigen binding loss and off-target toxicity. By systematically identifying the optimal ratio, Actinium has established a repeatable, scalable radiochemistry platform that enhances not only ATNM-400 but also its broader pipeline, including Actimab-A and Iomab-ACT. This capability addresses a widely recognized but under-solved industry issue in alpha-emitting radioconjugates, where suboptimal CAR has historically limited clinical translation despite promising preclinical activity. By owning this know-how, ATNM reduces reliance on external CDMOs, improves manufacturing consistency and safety profiles, and positions itself as a preferred partner for biopharmaceutical companies seeking to develop radiotherapies with favorable risk-benefit profiles—an intangible asset that is not fully reflected in current market valuations but could drive multiple inflection points as pipeline candidates progress toward clinical milestones in 2H 2026.

Actinium Pharmaceuticals (ATNM) is advancing a unique mutation-agnostic therapeutic platform centered on its lead candidate ATNM-400, a non-PSMA-targeted Actinium-225 antibody radioconjugate that demonstrates robust preclinical efficacy across multiple solid tumors including prostate cancer, non-small cell lung cancer (NSCLC), and breast cancer. Unlike PSMA-targeted therapies such as Pluvicto, which are limited by antigen heterogeneity and resistance mechanisms, ATNM-400 targets a novel antigen expressed in approximately 98% of NSCLC tumors and upregulated in resistant models, enabling activity in PSMA-negative and ARPI-resistant settings where current standards of care fail. This broad target expression, combined with evidence of synergistic effects when combined with EGFR or KRAS inhibitors—such as osimertinib yielding 107% tumor growth inhibition—positions ATNM-400 not as a niche agent but as a potential backbone therapy capable of enhancing existing standard-of-care regimens in large, commercially significant markets. The company’s focus on overcoming resistance mechanisms rather than competing in crowded mutation-specific lanes represents a structural shift in how targeted radiotherapies could be developed, with ATNM-400 poised to address unmet needs in patient populations exceeding 100,000 annually in mCRPC alone and tapping into NSCLC segments with peak sales estimates over $15 billion for EGFR inhibitors and $5 billion for KRAS inhibitors.
Actinium’s intellectual property strategy is reinforcing long-term defensibility and global scalability of its core programs, as evidenced by recent Notices of Allowance from the Canadian Intellectual Property Office (CIPO) for key patents covering Actimab-A in combination with CLAG-M for AML and Iomab-ACT for gene-edited cell-based therapies. These allowances, which build on existing protections in the U.S., Japan, and pending applications in Europe and China, extend patent coverage into 2038–2039, securing exclusivity for two of the company’s most advanced clinical-stage franchises. The Actimab-A patent protects a differentiated immunotherapy-chemotherapy backbone showing improved survival in relapsed/refractory AML, while the Iomab-ACT patent covers a targeted CD45 conditioning agent critical for enabling next-generation adoptive cell therapies, including gene-edited approaches like CAR-T. This expanding global IP estate—now encompassing approximately 250 issued and pending patents—creates formidable barriers to entry, supports premium partnership potential, and increases the likelihood of favorable outcomes in ongoing collaborations with institutions like the National Cancer Institute (NCI), thereby reducing execution risk and enhancing commercial leverage as these programs advance toward pivotal trials.
ATNM is leveraging its proprietary radiochemistry expertise to overcome a critical bottleneck in radiopharmaceutical development: chelator-to-antibody ratio (CAR) optimization. Recent SNMMI 2026 data demonstrated that precise CAR calibration directly improves tumor targeting, internalization, pharmacokinetics, and therapeutic index of 225Ac-labeled antibodies—turning a common formulation challenge into a proprietary advantage. Too low a CAR results in insufficient radiation delivery; too high causes antigen binding loss and off-target toxicity. By systematically identifying the optimal ratio, Actinium has established a repeatable, scalable radiochemistry platform that enhances not only ATNM-400 but also its broader pipeline, including Actimab-A and Iomab-ACT. This capability addresses a widely recognized but under-solved industry issue in alpha-emitting radioconjugates, where suboptimal CAR has historically limited clinical translation despite promising preclinical activity. By owning this know-how, ATNM reduces reliance on external CDMOs, improves manufacturing consistency and safety profiles, and positions itself as a preferred partner for biopharmaceutical companies seeking to develop radiotherapies with favorable risk-benefit profiles—an intangible asset that is not fully reflected in current market valuations but could drive multiple inflection points as pipeline candidates progress toward clinical milestones in 2H 2026.

▼ Bear case

Actinium Pharmaceuticals (ATNM) faces severe financial distress that threatens its operational continuity, as underscored by its non-compliance with NYSE American continued listing requirements due to stockholders' equity of only approximately $2.3 million as of March 31, 2026—well below the $4.0 million threshold required for companies with sustained losses. The company has reported net losses in each of its last five fiscal years, indicating a prolonged inability to generate positive cash flow from operations, and must submit a compliance plan by June 26, 2026, to avoid potential delisting proceedings that could commence if the plan is not accepted or if progress is insufficient. Even if a plan is accepted, ATNM must demonstrate meaningful improvement by November 27, 2027, or risk removal from the exchange, which would severely impair liquidity, increase financing costs, and deter institutional investment. This precarious financial position raises serious doubts about the company’s ability to fund expensive clinical trials, scale manufacturing, or sustain R&D efforts without dilutive financing or strategic transactions, casting doubt on the timeline and feasibility of advancing candidates like ATNM-400, Actimab-A, or Iomab-ACT toward commercialization despite promising preclinical data.
Despite encouraging preclinical results, ATNM’s pipeline remains predominantly in early stages, with no clinical-stage candidates having yet demonstrated pivotal efficacy in human trials, creating substantial execution risk that the market may be underestimating. ATNM-400, while showing strong activity in xenograft models across prostate cancer, NSCLC, and breast cancer, has not yet entered clinical testing, and the transition from preclinical success to clinical benefit in humans is historically low for radiopharmaceuticals due to complexities in biodistribution, dosimetry, manufacturing consistency, and unforeseen toxicities—particularly with alpha emitters like Ac-225, which carry risks of off-target cell damage if not precisely targeted. Similarly, Actimab-A, though supported by a CRADA with the NCI and showing improved survival in relapsed/refractory AML with CLAG-M, remains in early-phase development with no definitive data from later-stage trials to validate its potential as a therapeutic backbone. Iomab-ACT, while protected by patents, is still preclinical and faces uncertainty in its application to gene-edited cell therapies, a field that is itself evolving rapidly and subject to its own clinical and regulatory hurdles. Without near-term clinical validation, the company’s valuation remains highly speculative and vulnerable to disappointment if early trials fail to meet efficacy or safety expectations.
The radiopharmaceutical industry, while growing, is becoming increasingly competitive and capital-intensive, with multiple well-funded players entering the Ac-225 space and alternative therapeutic modalities posing external threats to ATNM’s long-term market position. Companies such as Bayer (with Pluvicto), Novartis, and numerous emerging biotechs are investing heavily in both PSMA-targeted and non-PSMA-directed alpha therapies, leveraging greater financial resources, established oncology franchises, and broader clinical trial infrastructure. ATNM’s reliance on a niche targeting antigen—while potentially advantageous in resistance settings—has not yet been validated at scale, and there is no guarantee that it will achieve sufficient tumor penetration or binding affinity to outperform emerging alternatives, including bispecifics, CAR-T cells armed with radioisotopes, or novel small molecule conjugates. Furthermore, the company’s dependence on external suppliers for critical raw materials like Ra-226—despite recent partnerships with QSA Global and NorthStar—introduces supply chain vulnerability, as any disruption in target production or regulatory delays in irradiation facilities could halt manufacturing. These competitive and operational pressures, combined with ATNM’s limited scale and cash constraints, suggest that its first-mover advantages may not be sustainable without significant additional investment, which may not be attainable given its current financial profile.

Actinium Pharmaceuticals (ATNM) faces severe financial distress that threatens its operational continuity, as underscored by its non-compliance with NYSE American continued listing requirements due to stockholders' equity of only approximately $2.3 million as of March 31, 2026—well below the $4.0 million threshold required for companies with sustained losses. The company has reported net losses in each of its last five fiscal years, indicating a prolonged inability to generate positive cash flow from operations, and must submit a compliance plan by June 26, 2026, to avoid potential delisting proceedings that could commence if the plan is not accepted or if progress is insufficient. Even if a plan is accepted, ATNM must demonstrate meaningful improvement by November 27, 2027, or risk removal from the exchange, which would severely impair liquidity, increase financing costs, and deter institutional investment. This precarious financial position raises serious doubts about the company’s ability to fund expensive clinical trials, scale manufacturing, or sustain R&D efforts without dilutive financing or strategic transactions, casting doubt on the timeline and feasibility of advancing candidates like ATNM-400, Actimab-A, or Iomab-ACT toward commercialization despite promising preclinical data.
Despite encouraging preclinical results, ATNM’s pipeline remains predominantly in early stages, with no clinical-stage candidates having yet demonstrated pivotal efficacy in human trials, creating substantial execution risk that the market may be underestimating. ATNM-400, while showing strong activity in xenograft models across prostate cancer, NSCLC, and breast cancer, has not yet entered clinical testing, and the transition from preclinical success to clinical benefit in humans is historically low for radiopharmaceuticals due to complexities in biodistribution, dosimetry, manufacturing consistency, and unforeseen toxicities—particularly with alpha emitters like Ac-225, which carry risks of off-target cell damage if not precisely targeted. Similarly, Actimab-A, though supported by a CRADA with the NCI and showing improved survival in relapsed/refractory AML with CLAG-M, remains in early-phase development with no definitive data from later-stage trials to validate its potential as a therapeutic backbone. Iomab-ACT, while protected by patents, is still preclinical and faces uncertainty in its application to gene-edited cell therapies, a field that is itself evolving rapidly and subject to its own clinical and regulatory hurdles. Without near-term clinical validation, the company’s valuation remains highly speculative and vulnerable to disappointment if early trials fail to meet efficacy or safety expectations.
The radiopharmaceutical industry, while growing, is becoming increasingly competitive and capital-intensive, with multiple well-funded players entering the Ac-225 space and alternative therapeutic modalities posing external threats to ATNM’s long-term market position. Companies such as Bayer (with Pluvicto), Novartis, and numerous emerging biotechs are investing heavily in both PSMA-targeted and non-PSMA-directed alpha therapies, leveraging greater financial resources, established oncology franchises, and broader clinical trial infrastructure. ATNM’s reliance on a niche targeting antigen—while potentially advantageous in resistance settings—has not yet been validated at scale, and there is no guarantee that it will achieve sufficient tumor penetration or binding affinity to outperform emerging alternatives, including bispecifics, CAR-T cells armed with radioisotopes, or novel small molecule conjugates. Furthermore, the company’s dependence on external suppliers for critical raw materials like Ra-226—despite recent partnerships with QSA Global and NorthStar—introduces supply chain vulnerability, as any disruption in target production or regulatory delays in irradiation facilities could halt manufacturing. These competitive and operational pressures, combined with ATNM’s limited scale and cash constraints, suggest that its first-mover advantages may not be sustainable without significant additional investment, which may not be attainable given its current financial profile.

Product and Service Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	211.73 Bn	24.22	5.56	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	180.92 Bn	-62.49	5.94	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	132.16 Bn	30.00	10.50	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	82.89 Bn	19.15	5.34	1.99 Bn
5	ARGX	Argenx Se	primary	61.41 Bn	35.80	11.75	-
6	MRNA	Moderna, Inc.	primary	53.99 Bn	-17.13	24.23	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	34.48 Bn	44.51	7.18	-
8	BIIB	Biogen Inc.	primary	31.15 Bn	37.32	3.11	8.09 Bn

Actinium Pharmaceuticals ATNM

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password